Pharmaceuticals & Healthcare Q3 Round-Up

 

BMI View: Innovative pharmaceutical companies will be making more concessions to governments, health systems and large payers in emerging markets. As in developed states, these stakeholders have limited budgets but also want to widen access to the latest treatments. Drugmakers should view these new types of arrangements as opportunities and not revenue-limiting. Conversely, the governments, health systems and large payers should seek equitable measures, otherwise pharmaceutical companies will invest elsewhere or seek market access through less favourable approaches.

Pharmaceuticals & Healthcare Q3 Round-Up
Product Price
$595.00

The Pharmaceuticals & Healthcare Q3 Round-Up features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Pharmaceuticals & Healthcare Q3 Round-Up provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Global pharmaceutical and healthcare industry.